Clinical Efficacy Analysis Of Smile Pro Surgery For Myopia And Astigmatism Correction At 3 Months Postoperative

To investigate the 3-month postoperative clinical efficacy of SMILE PRO surgery for myopia and astigmatism correction, and to provide data support for clinical application.

 Traditional SMILE techniques still face challenges in achieving precise correction for patients with moderate to high astigmatism, which may affect postoperative visual quality. SMILE PRO, an upgraded version integrated with intelligent positioning and spin compensation systems, is designed to enhance refractive accuracy, especially for astigmatism correction. Yet, clinical evidence regarding its 3-month postoperative efficacy remains to be systematically verified.

This was a retrospective clinical study. The subjects were patients who underwent SMILE PRO surgery at our hospital using the ZEISS VISUMAX 800 device combined with the CentraLign intelligent positioning system and OcuLign spin compensation system. At 3 months postoperatively, uncorrected distance visual acuity (UDVA), best-corrected distance visual acuity (CDVA), residual spherical equivalent, residual astigmatism were evaluated. The safety, effectiveness, and stability of the surgery were analyzed, especially in patients with high myopia and astigmatism.

A total of 136 eyes from 68 patients who underwent SMILE PRO surgery were enrolled in the study at 3 months postoperatively. The preoperative mean spherical equivalent refractive error was -5.62±1.57D and -5.21±1.69D respectively. Among the SMILE PRO group, 87.6% of the eyes achieved a postoperative spherical equivalent within ±0.50D of the target refraction, and 98.7% within ±1.00D. Additionally, 99% of the eyes had a UDVA ≥1.0, and 67% had a UDVA ≥1.2. Moreover, 50.7% of the eyes achieved a UDVA better than the preoperative CDVA, and 93.6% had residual astigmatism ≤0.5D. The postoperative mean astigmatism was 0.07D×175°, with a target-induced astigmatism (TIA) of 0.61D×178.1° and a surgically induced astigmatism (SIA) of 0.54D×178.4°.

SMILE PRO surgery exhibits significant efficacy and excellent stability for myopia and astigmatism correction at 3 months postoperatively. It is characterized by high efficiency, precision, and safety, and shows superior adaptability for patients with high astigmatism and high visual quality requirements, thus possessing prominent clinical application value.